Impedimed Limited · ASX:IPD
Impedimed — Investor Presentation (October 2013)
24 slides from Impedimed's investor presentation, Oct 14, 2013
Slide 1: Investor Presentation
For personal use only Investor Presentation (ASX:IPD) October 2013 L-Dex® becoming the standard of care for all cancer patients at risk of developing lymphoedema 1
Slide 2: Disclaimer
Disclaimer • This presentation has been produced by ImpediMed Limited (“ImpediMed”) only and may contain forward-looking statements that are based on management’s current expectations, beliefs and assumptions and are subject to a number of risks and For personal use only uncertainties. The forward-l
Slide 3: Company Snapshot
Company Snapshot For personal use only Corporate Financials (at 30 June 2013) Australian listed company: Cash and cash equivalents: • ASX: IPD • $7.3 million Operations: Cash burn: • Brisbane (AUS) • $4.9 million 1st half FY13 • San Diego (USA) • $2.3 million 2nd half FY13 Listing date: ImpediMed -
Slide 4: New Executive Team
New Executive Team Proven Record of Success For personal use only Rick joined ImpediMed in July 2013 with an impressive thirty year record for building world-class organisations for global corporations in the medical technology and consumer goods industries, including a twelve year executive career
Slide 5: FY13 - Transforming the Business
FY13 - Transforming the Business For personal use only New Direction • New CEO • New executive team • New strategy New Focus • Building the core lymphoedema business • Clinical requirements and regulatory pathway • Clear reimbursement plan of action • Expand the technology platform • Strong financia
Slide 6: Significant Progress and Milestones Achieved in FY13
Significant Progress and Milestones Achieved in FY13 For personal use only Q1 Q2 Q3 Q4 • New CEO starts • Discussions begin with • 3M becomes exclusive • FDA 510(k) clearance 3M Australia sales agent for Australia received • Phase I of company and New Zealand restructuring executed • Kaiser Permanen
Slide 7: Kaiser Permanente Expansion
Kaiser Permanente Expansion For personal use only Expansion Sites One of the nations largest Southern California Region not-for-profit health plans • 1 Hospital Hospitals 37 • 2 Outpatient Centers Medical offices and Initial Sites outpatient facilities 611 Northern California Region Physicians 17,15
Slide 8: New Executive Team's Strategy of Focusing on Lymphoedema Revenue Growth is Paying Off
New Executive Team’s Strategy of Focusing on Lymphoedema Revenue Growth is Paying Off For personal use only Total Revenue Lymphoedema Revenue Lymphoedema Mix ($) FY13 $4.0 $1.5 • Global US lymphoedema business grows 35% in FY13 $3.0 $1.1 96% 4% • Short-term actions taken to begin shifting the Millio
Slide 9: Dramatically Improving Financial Position
Dramatically Improving Financial Position Expenses Months of Cash On Hand For personal use only $4.0 20 19 18 • Focusing on the 17 growth of the core $3.0 15 lymphoedema business 13 • Carefully scrutinising 12 Months all expenditures has Millions $2.0 10 allowed us to reduce expenses by $4.7 million
Slide 10: Lymphoedema is a Significant Unmet Medical Need
Lymphoedema is a Significant Unmet Medical Need For personal use only An estimated 3 million people develop secondary lymphoedema each year due to cancer One out of every three survivors of breast, pelvic (including gynaecological and prostate), or melanoma cancer will develop lymphoedema Current de
Slide 11: L-Dex: The only FDA Cleared Technology for the Assessment of Lymphoedema
L-Dex: The only FDA Cleared Technology for the Assessment of Lymphoedema For personal use only • A hand held device designed specifically to assist in clinical assessment and monitoring of lymphoedema • Bioimpedance Spectroscopy (BIS), Class II Medical Device • FDA cleared, ARTG listed, CE marked •
Slide 12: L-Dex: Key to Early Detection of Lymphoedema
L-Dex: Key to Early Detection of Lymphoedema For personal use only L-Dex technology (BIS) is a direct measure of extra cellular fluid (ECF), all other techniques used today measure volume Figures demonstrate the advantage in longitudinally monitoring extracellular fluid levels versus total limb volu
Slide 13: L-Dex Provides Significant Advantages
L-Dex Provides Significant Advantages For personal use only Direct Volume Detects Sub- Standardised Ease for Measure of Change Easily Regulatory Time Required Standard of Method Extra-cellular Clinical Required for Detection Reproducible Clearance Patients, to Test Portable Care (Stage 0) Criteria N
Slide 14: Lymphoedema Market
Lymphoedema Market For personal use only Current Clinical Practice for Incidence Rates L-Dex Readings Cleared Markets Cancer* Lymphoedema Total Number of Time and Protocol L-Dex Readings 8,245 2,720 Year 1 Base line plus 5 46,723 15,419 quarterly readings Years 2-4 582,200 192,126 Annual or quarterl
Slide 15: Significant Growth Opportunities
Significant Growth Opportunities For personal use only Lymphoedema Consumable Market $1 Phase III - Expand into High Billion Potential Geographies { } Regulatory Cleared Markets $312 Phase II - Lower Limb and Million Melanoma Cancers $104 Million } Phase I - Breast Cancer (underway) 15
Slide 16: Value Proposition
Value Proposition For personal use only Early Detection • Enables early treatment • Enhances treatment options Because... • Emerging data shows a 97% reduction in lymphoedema progressing beyond stage 0 if detected early and treated effectively Which... • Improves patient outcomes • Improves quality
Slide 17: Competitive Landscape
Competitive Landscape For personal use only Short Term • Tape Measure • Declining Reimbursement • No single physician is responsible for the patient over the cancer care continuum Perceived Threats • Pharmacological - requires detection and monitoring • Surgical techniques - requires detection and m
Slide 18: Key Objectives and Milestones
Key Objectives and Milestones For personal use only • Add U.S. Healthcare experienced board members • Pivotal Clinical Trial - first enrollment 2014 • Develop new and / or expand existing strategic partnerships • Expand use of our devices for drug and / or therapeutic clinical trials • CPT Category
Slide 19: Investment Case
Investment Case For personal use only • Highly experienced executive team • First mover advantage in lymphoedema market • Substantial IP portfolio • Proven technology • Regulatory clearances in AU, US, and EU • L-Dex is the assessment tool, the metric, and ImpediMed's registered trademark • Low valu
Slide 20: Appendix
For personal use only 20 Appendix
Slide 21: Second U.S. Board Member
Second U.S. Board Member For personal use only ASX ANNOUNCEMENT 8th October 2013 For personal use only IMPEDIMED APPOINTS ITS SECOND US DIRECTOR ImpediMed founder and long time chairman, Mel Bridges, retires David Adams to join ImpediMed board at AGM. Brisbane, Australia – ImpediMed Limited (ASX
Slide 22: Board of Directors
Board of Directors Experienced and Influential For personal use only Cherrell Hirst, AO FTSE Cherrell Hirst is a medical doctor and was a leading practitioner in the area of breast cancer screening and diagnosis. Cherrell serves as the Chairman of the Board. Cherrell was appointed Deputy Chairman on
Slide 23: Lymphoedema
Lymphoedema For personal use only Lymphoedema is the build-up of fluid in soft body tissues when the lymph system is damaged or blocked. Lymphoedema occurs when the lymph system is damaged or blocked. Fluid builds up in soft body tissues and causes swelling. It is a common problem that may be caused
Slide 24: Stages of Lymphoedema
Stages of Lymphoedema For personal use only Stage 0 (or Ia) which refers to a latent or sub-clinical condition where swelling is not evident despite impaired lymph transport. It may exist months or years before overt oedema occurs (Stages I-III). Stage I represents an early accumulation of fluid rel